Background {#Sec1}
==========

The classification of the hereditary ataxias has represented a challenge for decades due to the large heterogeneity of clinical presentations and the important overlap between different pathologies \[[@CR1]\]. The first to propose a global classification for this group of disorders was Greenfield in 1954, whose classification was based on pathoanatomical findings \[[@CR2]\]. This was followed by Harding's classification in 1983, which regrouped the ataxias according to age of onset, as a proxy for mode of inheritance, and clinical findings \[[@CR3]\]. Although this clinical classification had merit, it quickly became overshadowed by a nomenclature based on gene discoveries within each specific type of ataxia starting with *ATXN1* in Spinocerebellar ataxia 1 in 1993 \[[@CR4]\] and *FXN* in Friedreich ataxia \[[@CR5]\]. Since then, over 40 genes have been discovered in the dominant ataxias and as many in recessive ataxias \[[@CR6]\].

One of the main challenges in the study of recessive ataxias is the difficulty to properly circumscribe which disorders belong to the field of hereditary ataxias and which belong to other disease categories. Indeed, ataxia is a cardinal symptom in cerebellar disorders, but may also be a presenting symptom of hereditary spastic paraplegias, hereditary polyneuropathies, neurodevelopmental disorders, and mitochondrial diseases, for example. Concurrently, recessive ataxias often manifest with complex phenotypes, even more so than their dominant counterparts, and may present diverse associated features including neuropathy, pyramidal and extrapyramidal involvement, oculomotor abnormalities, cognitive involvement, seizures, retinopathy, hypogonadism, and many others. This explains the high variability in the list of included disorders in recent literature reviews on recessive ataxias \[[@CR7], [@CR8]\].

Nevertheless, the advent of next generation sequencing techniques requires to properly determine which disorders belong to each disease category in order to design thoughtful targeted panels and facilitate the interpretation of whole exome and whole genome sequencing data. Indeed, targeted panel sequencing is a highly effective method for the diagnosis of neurological disorders, but it requires insightful categorization of disease phenotypes to respond to the specific needs of clinicians \[[@CR9], [@CR10]\]. Similarly, the interpretation of unknown variants in the analysis of whole exome or whole genome sequencing data poses a significant challenge for clinicians who must determine if the gene is associated with the suspected disease category and if the phenotype correlates with what has previously been described. As next generation sequencing techniques become increasingly available and the ability to detect DNA repeat expansion diseases improves \[[@CR11]\], the proper classification of diseases will represent a useful tool in the interpretation of test results. Hence, this calls for a systematic effort to review recessive diseases in which ataxia is a prominent feature in order for experts in the field to collectively determine which disorders should be included in a recessive ataxia classification.

Therefore, the purpose of this article is to review the literature on recessive diseases presenting with ataxia in order to present a new classification. The goal is to bring together experts for the development of a much-needed consensus that fulfills research and clinical needs.

Methods {#Sec2}
=======

We conducted a systematic review to identify articles relevant to the classification of autosomal recessive ataxias. We searched Pubmed and Embase from inception to September 2016 in order to identify original articles on disorders presenting with ataxia. The search strategy was large and targeted both recessive and sporadic ataxias, since recessive inheritance may appear sporadic in certain circumstances (full search strategy is provided in Additional file [1](#MOESM1){ref-type="media"}). We also reviewed reference lists of relevant articles and public databases including OMIM and GeneReviews to identify other relevant articles.

We reviewed the titles and abstracts of all identified references to select original articles on recessive forms of ataxia in humans for which a causative gene was identified. We evaluated the articles from a clinical perspective to determine if cerebellar ataxia was a prominent feature in the reported patients or rather a secondary finding in other movement or multisystem diseases. Diseases reporting only on cerebellar atrophy or cerebellar malformations without any clinical consequence were not included. For each listed disorder, we reviewed the evidence for a genotype-phenotype association using the US National Human Genome Research Institute guidelines \[[@CR12]\]. Major considerations included the exclusion of previously described genes, the number of unrelated individuals described with similar genotype-phenotype correlations, the evidence of segregation with the disease, the absence of the variant in large control cohorts, and the presence of biochemical or animal-model functional validation. For the primary ataxias, we identified two relevant references from different research groups when possible. All relevant articles were fully reviewed to be included in this classification of recessive ataxias.

Identified disorders were classified in three categories: the first included the primary autosomal recessive ataxias, the second included other movement or multisystem recessive diseases that have prominent ataxia, and the final group was composed of recessive disorders that may occasionally present with ataxia, but where ataxia is a secondary feature.

We also developed a clinical algorithm for the primary recessive ataxias based on the most frequent phenotype and cardinal symptoms associated with each disorder. The objective of this algorithm is to rapidly summarize the main discriminatory features between different ataxias to serve in a clinical setting, but also as a pedagogical and research tool.

Results {#Sec3}
=======

3750 references were identified through the literature search in Pubmed and Embase, and 49 additional references were identified through reference lists or public databases. After removal of duplicates, 2354 references were reviewed on the basis of title and abstract. Finally, 130 articles were selected on the basis of the aforementioned criteria and completely reviewed to be included in this qualitative analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram

The proposed new list of autosomal recessive ataxias is presented in Table [1](#Tab1){ref-type="table"} in chronological order of gene discovery. The disorders included in this list were evaluated as having a relatively predominant cerebellar involvement compared to the involvement of other neurologic and non-neurologic systems. Table [2](#Tab2){ref-type="table"} presents the other complex motor or multisystem disorders that have prominent ataxia. Finally, Table [3](#Tab3){ref-type="table"} presents disorders that may occasionally present with ataxia, but where ataxia is a secondary feature. Certain decisions were made in the elaboration of this classification. Notably, abetalipoproteinemia (ABL) and Refsum disease were not included in the list of primary recessive ataxias, but rather in the list of complex disorders that have prominent ataxia. Indeed, despite their important Friedreich-like neurological picture, these disorders are primary lipid metabolism disorders with multisystem involvement. Moreover, ataxic disorders that are allelic to other movement disorders, especially spinocerebellar ataxias and hereditary spastic paraplegias, were assigned to the second category to avoid any confusion with the primary recessive ataxias. The MARS2-linked autosomal recessive ataxia with leukoencephalopathy (ARSAL/SPAX3) was not included because the genetic evidence was deemed insufficient \[[@CR13]\]. Finally, some disorders described only in single families were included, despite this being a factor for weaker genetic evidence, if other major considerations were met; this was indicated in the list.Table 1Proposed new list of autosomal recessive ataxiasDisorderGeneOMIMAdditional clinical features and neuroimaging findingsRelevant referencesCTX*CYP27A1*213700Dementia, paresis, tendon xanthomas, atherosclerosis, cataracts, elevated cholestanol level, childhood onset, variable cerebellar atrophy, cerebellar or cerebral leukodystrophy\[[@CR17], [@CR18]\]AVED*TTPA*277460Retinitis pigmentosa, head titubation, low serum vitamin E, teenage onset, spinal cord atrophy, absence of cerebellar atrophy\[[@CR19], [@CR20]\]AT*ATM*208900Telangiectasias, oculomotor apraxia, photosensitivity, immunodeficiency, predisposition for cancer, elevation of α-foetoprotein, infantile onset, cerebellar atrophy\[[@CR21], [@CR22]\]FRDA*FXN*229300Bilateral Babinski sign, square-wave jerks, scoliosis, hypertrophic cardiomyopathy, sensory involvement, teenage onset, spinal cord atrophy, absence of cerebellar atrophy\[[@CR5], [@CR23]\]ATLD*MRE11*604391Oculomotor apraxia, childhood onset, cerebellar atrophy\[[@CR24], [@CR25]\]ARSACS*SACS*270550Spastic paraparesis, retinal striation, pes cavus, infantile or childhood onset, anterior superior cerebellar atrophy, occasional T2-weighted linear hypointensities in pons\[[@CR26], [@CR27]\]AOA1/EAOH*APTX*208920Oculomotor apraxia, cognitive impairment, hypoalbuminemia, hypercholesterolemia, childhood onset, cerebellar atrophy\[[@CR28], [@CR29]\]SCAN1*TDP1*607250Peripheral axonal sensorimotor neuropathy, distal muscular atrophy, hypercholesterolemia, teenage onset, cerebellar atrophy\[[@CR30], [@CR31]\]Cayman ataxia*ATCAY*601238Psychomotor retardation, hypotonia, strabism, neonatal onset, cerebellar hypoplasia\[[@CR32], [@CR33]\]SANDO or MIRAS/SCAE*POLG1*607459In SANDO, sensory ataxia, ophtalmoparesis, myoclonus, ptosis, adult onset, variable cerebellar atrophy, cerebellar white matter lesions, strokelike lesions. In MIRAS, cerebellar and sensitive ataxia, epilepsy, migraine, myoclonus, childhood or teenage onset, signal abnormalities in cerebellum and thalamus\[[@CR34], [@CR35]\]AOA2*SETX*606002Polyneuropathy, pyramidal signs, oculomotor apraxia, head tremor, chorea, dystonia, elevation of α-foetoprotein, teenage onset, cerebellar atrophy\[[@CR36], [@CR37]\]CAMRQ1, DES*VLDLR*224050Non-progressive cerebellar ataxia, mental retardation, hypotonia, strabismus, occasional quadripedal gait, congenital onset, inferior cerebellar hypoplasia, cortical gyral simplification\[[@CR38], [@CR39]\]IOSCA/MTDPS7 (Allelic to PEOA3)*C10orf2*271245Athetosis, hypotonia, optic atrophy, ophtalmoplegia, hearing loss, epilepsy, hypogonadism, liver involvement, infantile onset, moderate atrophy of brainstem and cerebellum with advancing disease\[[@CR40], [@CR41]\]MSS*SIL1*248800Cataracts, mental retardation, myopathy, short stature, childhood onset, cerebellar atrophy\[[@CR42], [@CR43]\]DCMA/MGCA5*DNAJC19*610198Dilated cardiomyopathy, non-progressive cerebellar ataxia, mental retardation, testicular dysgenesis, anemia, increased urinary 3-methylglutaconic acid, infantile onset\[[@CR44], [@CR45]\]ARCA1*SYNE1*610743Pure cerebellar ataxia, cognitive impairment, occasional pyramidal signs, late onset, cerebellar atrophy\[[@CR46], [@CR47]\]ARCA2*ADCK3* (*CABC1*)612016Exercise intolerance, epilepsy, myoclonus, cognitive impairment, childhood onset, cerebellar atrophy, occasional strokelike cerebral lesions\[[@CR48], [@CR49]\]SeSAME syndrome*KCNJ10*612780Epilepsy, sensorineural deafness, mental retardation, tubulopathy and electrolyte imbalance, infantile onset, absence of cerebellar atrophy\[[@CR50], [@CR51]\]CAMRQ3*CA8*613227Mild mental retardation, occasional quadrupedal gait, congenital onset, cerebellar atrophy, white matter abnormalities\[[@CR52], [@CR53]\]Salih ataxia/SCAR15 (1 family)KIAA0226615705Epilepsy, mental retardation, childhood onset, absence of cerebellar atrophy\[[@CR54], [@CR55]\]PHARC*ABHD12*612674Sensorimotor neuropathy, cataract, hearing loss, retinitis pigmentosa, teenage onset, variable cerebellar atrophy\[[@CR56], [@CR57]\]SPAX4 (1 family)*MTPAP*613672Spastic paraparesis, optic atrophy, cognitive involvement, infantile onset\[[@CR58], [@CR59]\]ARCA3*ANO10*613728Cognitive impairment, downbeat nystagmus, teenage or adult onset, cerebellar atrophy\[[@CR60], [@CR61]\]SCAR11 (1 family)*SYT14*614229Psychomotor retardation, late onset, cerebellar atrophy\[[@CR62]\]CAMRQ2*WDR81*610185Occasional quadrupedal gait, cognitive impairment, congenital onset, hypoplasia of cerebellum and corpus callosum\[[@CR63], [@CR64]\]AOA3 (1 family)*PIK3R5*615217Oculomotor apraxia, sensorimotor involvement, teenage onset, cerebellar atrophy\[[@CR65]\]SCAR13*GRM1*614831Cognitive impairment, mild pyramidal signs, short stature, seizures, congenital onset, cerebellar atrophy\[[@CR66], [@CR67]\]CAMRQ4 (1 family)*ATP8A2*615268Cognitive impairment, occasional quadrupedal gait, congenital onset, cerebellar and cerebral atrophy\[[@CR68]\]SCAR7 (Allelic to CLN2)*TPP1*609270Pyramidal signs, posterior column involvement, tremor, childhood onset, atrophy of the cerebellum and pons\[[@CR69], [@CR70]\]Ataxia and hypogonadotropism*RNF216*212840Hypogonadotropic hypogonadism, dementia, occasional chorea, childhood to young adult onset, cerebellar and cerebral atrophy\[[@CR71], [@CR72]\]SCAR18*GRID2*616204Tonic upgaze, psychomotor retardation, retinal dystrophy, infantile onset, cerebellar atrophy\[[@CR73], [@CR74]\]SCAR16*STUB1*615768Pyramidal signs, neuropathy, occasional hypogonadism, variable age at onset, cerebellar atrophy\[[@CR75], [@CR76]\]SCAR12*WWOX*614322Tonic-clonic epilepsy, mental retardation, spasticity, neonatal to childhood onset, variable cerebellar or cerebral atrophy\[[@CR77], [@CR78]\]ATLD2 (1 family)*PCNA*615919Telangiectasias, sensorineural hearing loss, photosensitivity, cognitive impairment, short stature, childhood onset, cerebellar atrophy\[[@CR79]\]SCAR20*SNX14*616354Mental retardation, sensorineural hearing loss, macrocephaly, dysmorphism, infantile onset, cerebellar atrophy\[[@CR80], [@CR81]\]SCAR17*CWF19L1*616127Mental retardation, congenital onset, cerebellar hypoplasia\[[@CR82], [@CR83]\]ACPHD (1 family)*DNAJC3*616192Diabetes mellitus, UMN signs, demyelinating neuropathy, sensorineural hearing loss, childhood to adult onset, generalized supra- and infratentorial atrophy\[[@CR84]\]LIKNS/SCAR19 (1 family)*SLC9A1*616291Sensorineural hearing loss, childhood onset, variable vermian atrophy\[[@CR85]\]AOA4 (Allelic to MCSZ)*PNKP*616267Dystonia, oculomotor apraxia, polyneuropathy, cognitive impairment, childhood onset, cerebellar atrophy\[[@CR86], [@CR87]\]SCAR2*PMPCA*213200Non-progressive cerebellar ataxia, cognitive impairment, pyramidal signs, short stature, congenital or infantile onset, cerebellar atrophy\[[@CR88], [@CR89]\]SCAR21*SCYL1*616719Liver failure, peripheral neuropathy, mild cognitive impairment, childhood onset, cerebellar vermis atrophy, thinning of optic nerve\[[@CR90]\]SCAR22 (1 family)*VWA3B*616948Cognitive impairment, pyramidal signs, adult onset, cerebellar atrophy and thin corpus callosum\[[@CR91]\]SCAR23 (1 family)*TDP2*616949Tonic seizures, cognitive impairment, dysmorphism, childhood onset\[[@CR92]\]SCAR24 (1 family)*UBA5*617133Cataracts, peripheral neuropathy, childhood onset, cerebellar atrophy\[[@CR93]\]Cerebellar ataxia with developmental delay (1 family)*THG1L*-Psychomotor retardation, pyramidal signs, childhood onset, vermis hypoplasia\[[@CR94]\]*ACPHD* Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, *AOA* ataxia with oculomotor apraxia, *ARCA* autosomal recessive cerebellar ataxia, *ARSACS* autosomal recessive spastic ataxia of Charlevoix-Saguenay, *AT* ataxia-telangiectasia, *ATLD* ataxia-telangiectasia-like disorder, *AVED* ataxia with vitamin E deficiency, *CA* Cayman ataxia, *CAMOS* cerebellar ataxia mental retardation optic atrophy and skin abnormalities, *CAMRQ* cerebellar ataxia mental retardation with or without quadrupedal locomotion, *DCMA* Dilated cardiomyopathy with ataxia, *DES* Desequilibrium syndrome, *EAOH* early-onset ataxia with oculomotor apraxia and hypoalbuminemia, *FRDA* Friedreich ataxia, *IOSCA* infantile onset spinocerebellar ataxia, *LIKNS* Lichtenstein-Knorr syndrome, *MGCA5* 3-methyglutaconic aciduria type 5, *MIRAS* mitochondrial recessive ataxia syndrome, *MCSZ* Microchephaly seizures developmental delay, *MSS* Marinesco-Sjogren syndrome, MTDPS7 mitochondrial DNA depletion syndrome 7, *PEOA3* progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, *PHARC* polyneuropathy hearing loss ataxia retinitis pigmentosa and cataract, *SANDO* sensory ataxic neuropathy with dysarthria and ophthalmoparesis, *SCAE* spinocerebellar ataxia with epilepsy, *SCAN1* spinocerebellar ataxia with axonal neuropathy 1, *SCAR* Spinocerebellar ataxia, autosomal recessive, *SeSAME* Seizures sensorineural deafness ataxia mental retardation and electrolyte imbalance, *SPAX* spastic ataxia, *UMN* upper motor neuron Table 2Other complex movement or multisystem recessive disorders that have prominent ataxiaDisorderGeneOMIMClinical features and imaging findingsCommentReferencesAbetalipoproteinemia*MTTP*200100Fat malabsorption symptoms, hypocholesterolemia, hypotriglyceridemia, acanthocytosis, Friedreich-like ataxia, neonatal onset, absence of cerebellar atrophyMultisystem\[[@CR95]\]Nieman Pick type C*NPC1*257220Vertical supranuclear ophtalmoplegia, ataxia, splenomegaly, childhood to adult onset, variable cerebellar or cerebral atrophyMultisystem\[[@CR96], [@CR97]\]*NPC2*607625Refsum disease*PAHX*266500Retinitis pigmentosa, polyneuropathy, ataxia, increased CSF protein, anosmia, deafness, ichtyosis, teenage onset, elevated serum phytanic acid, absence of cerebellar atrophyMultisystem\[[@CR98], [@CR99]\]Late-onset GM2 gangliosidosis (Tay-Sachs, Sandhoff)*HEXA HEXB*272800 268800Ataxia, dysarthria, intellectual impairment, extrapyramidal signs, adult onset, cerebellar atrophyLysosomal storage disease\[[@CR100]--[@CR102]\]SPARCA1*SPTBN2*615386Ataxia, cognitive impairment, eye-movement abnormalities, early childhood onset, cerebellar atrophyAllelic to SCA5\[[@CR9], [@CR103]\]SPAX5*AFG3L2*614487Ataxia, spasticity, oculomotor apraxia, myoclonic epilepsy, neuropathy, dystonia, optic atrophy, childhood onset, cerebellar atrophyAllelic to SCA28\[[@CR104], [@CR105]\]Boucher-Neuhauser/Gordon Holmes syndrome*PNPLA6*215470Ataxia, hypogonadotropic hypogonadism, chorioretinal dystrophy or brisk reflexes, childhood onset, atrophy of cerebellum and ponsAllelic to HSP39\[[@CR106], [@CR107]\]Gillespie syndrome*ITPR1*206700Non-progressive cerebellar ataxia, iris hypoplasia, cognitive impairment, neonatal onset, progressive cerebellar atrophyAllelic to SCA15/29\[[@CR108]\]SPAX2/SPG58*KIF1C*611302Spastic paraparesis, cerebellar ataxia, childhood or teenage onset, white matter changes in the internal capsuleSpasticity predominant\[[@CR109], [@CR110]\]SPG7*SPG7*607259Spasticity, pyramidal signs, cerebellar signs, optic neuropathy, ptosis, teenage or adult onset, cerebellar atrophyHSP\[[@CR111], [@CR112]\]SPG5*CYP7B1*270800Spasticity, cerebellar and sensory ataxia, childhood or teenage onset, white matter lesionsHSP\[[@CR113], [@CR114]\]SPG11*KIAA1840*604360Spasticity, ataxia, cognitive impairment, sensorimotor neuropathy, childhood or teenage onset, thin corpus callosum, signal abnormalities in cervical cordHSP\[[@CR115], [@CR116]\]SPG46*GBA2*614409Cerebellar ataxia, spastic dysarthria, mild cognitive impairment, hearing loss, cataracts, childhood onset, cerebellar and cerebral atrophy, thin corpus callosumHSP\[[@CR117], [@CR118]\]Congenital disorders of glycosylation type 1A*PMM2*212065Psychomotor retardation, axial hypotonia, abnormal eye movements, peripheral neuropathy, congenital onset, cerebellar hypoplasiaNeonatal onset, complex syndrome\[[@CR119], [@CR120]\]LBSL*DARS2*611105Cerebellar ataxia, tremor, spasticity, dorsal column dysfunction, axonal neuropathy, childhood to adult onset, signal abnormalities in cerebral white matter and specific brainstem and spinal cord tractsLeukoencephalopathy\[[@CR121], [@CR122]\]Mitochondrial complex IV deficiency*COX20*220110Cerebellar ataxia, dystonia, sensory axonal neuropathy, variable, childhood or teenage onset, cerebellar atrophyDystonia predominant\[[@CR123]\]Aceruloplas-minemia*CP*604290Diabetes, dementia, movement disorder, cerebellar ataxia, retinal degeneration, late onset, decreased signal intensity in thalamus, basal ganglia and dentate nucleusMetabolic disorder\[[@CR124]\]Neurodegeneration with brain iron accumulation 2A and 2B*PLA2G6*256600Cerebellar ataxia, psychomotor retardation, psychiatric features, axonal sensorimotor neuropathy, infantile or teenage onset, cerebellar atrophy and variable iron accumulation in globus pallidusNeurodegeneration with brain iron accumulation\[[@CR125], [@CR126]\]Poretti-Botshauser syndrome*LAMA1*615960Nonprogressive ataxia, oculomotor ataxia, psychomotor retardation, early childhood onset, cerebellar dysplasia with cystsDystroglycanopathy\[[@CR127]\]Posterior column ataxia with retinitis pigmentosa*FLVCR1*609033Posterior column degeneration and retinitis pigmentosa, childhood onset, signal abnormalities in cervical spinal cordSensory ataxia\[[@CR128], [@CR129]\]*HSP* hereditary spastic paraplegia, *LBSL* leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation, *SPARCA1* spectrin-associated autosomal recessive cerebellar ataxia type 1, *SPAX* spastic ataxia, *SPG* spastic paraplegia Table 3Recessive disorders that may occasionally present with ataxia, but where ataxia is a secondary featureDisorderGeneOMIMClinical features and imaging findingsCommentReferencesNeuronal ceroid lipofuscinoses*CLN5 CLN6*256731 601780Psychomotor retardation, visual failure, seizures, childhood to teenage onset, cerebellar and cerebral atrophyAtaxia is a rare feature\[[@CR130], [@CR131]\]Sialic acid storage diseases (ISSD and Salla disease)*SLC17A5*604369 269920Hypotonia, cerebellar ataxia and mental retardation, infantile to adult onset, cerebellar atrophy and demyelinationComplex syndrome\[[@CR132], [@CR133]\]Joubert syndrome*AHI1*, *ARL13B*, *CC2D2A*, othersManyAtaxia, hypotonia, neonatal breathing abnormalities, mental retardation, nephronophtisis, congenital onset, agenesis of the cerebellar vermisComplex neonatal polygenic syndrome\[[@CR134], [@CR135]\]Hartnup disorder*SLC6A19*234500Transient manifestations of pellagra, cerebellar ataxia and psychosis, amino aciduria, early onsetMetabolic disorder\[[@CR136]\]Childhood ataxia with central nervous system hypomyelination/vanishing white matter disease*elF2B*603896Cerebellar ataxia with spasticity. Rapid deterioration following head trauma or febrile illness, infantile to adult onset, diffusely abnormal cerebral white matterLeukodystrophy\[[@CR137], [@CR138]\]L-2-Hydroxyglutaric aciduria*L2HGDH*236792Psychomotor retardation, epilepsy, macrocephaly, cerebellar ataxia, infantile onset, subcortical leukoencephalopathy and cerebellar atrophyMetabolic disorder\[[@CR139], [@CR140]\]GOSR2-linked progressive myoclonus epilepsy*GOSR2*614018Ataxia, myoclonic epilepsy, raised creatine kinase, early childhood onset, variable cerebellar and cerebral atrophyEpileptic disorder\[[@CR141]\]Tremor-ataxia with central hypomyelination*POLR3A*607694Tremor, cerebellar ataxia, cognitive regression, UMN signs, childhood onset, hypomyelination of deep white matter, cerebellar atrophy, thin corpus callosumLeukodystrophy\[[@CR142]\]Recessive Behr's syndrome*OPA1*210000Optic atrophy, ataxia, peripheral neuropathy, digestive symptoms, infantile or childhood onset, cerebellar atrophyOptic atrophy\[[@CR143], [@CR144]\]*ISSD* infantile sialic acid storage disease

The primary recessive ataxias were also organized in a clinical algorithm (Fig. [2](#Fig2){ref-type="fig"}) according to the presence of key clinical clues, which include the presence of sensorimotor involvement, cognitive impairment, spasticity, and oculomotor abnormalities.Fig. 2Clinical algorithm of autosomal recessive ataxias

Other disorders have been reported with ataxia, but the authors evaluated that these disorders did not need to be included in the differential diagnosis of recessive ataxias. However, clinicians may bear in mind that the following may have ataxia as an associated feature: Lafora disease (EPM2A, EPM2B), megalencephalic leukoencephalopathy with subcortical cysts (MLC1), COL18A1-linked ataxia epilepsy cognitive problems and visual problems, Perrault syndrome (HSD17B4), Zellweger-spectrum disorders (PEX2), Wolfram syndrome (WFS1), Canavan disease (ASPA), metachromatic leukodystrophy (ARSA), Galloway-Mowat syndrome (WDR73), and GLUT-1 deficiency (SCL2A1).

Discussion {#Sec4}
==========

We present a new classification for the autosomal recessive ataxias. This classification should allow for better categorization of recessive disorders presenting with ataxia with a clear separation between the primary recessive ataxias and disorders that may present with ataxia as an associated feature but belong to other disease categories. We also provided a clinical algorithm as a tool for diagnostic, learning, and research purposes. This comprehensive classification will allow for improved genetic diagnosis by targeted next generation sequencing applications as the ability to detect DNA repeat expansion diseases is quickly becoming a reality with prospects of treatment in the future \[[@CR11], [@CR14], [@CR15]\].

As compared to previously published reports on this subject \[[@CR7], [@CR8]\], we systematically reviewed the literature to evaluate the available evidence on the disease-associated genes in order to include all disorders presenting with a predominant cerebellar ataxia phenotype. The systematic review methodology with a structured data search and comprehensive evaluation of all references allowed for a complete evaluation of the literature regarding disorders presenting with ataxia to ensure that all potentially relevant disorders were included in this classification. Nevertheless, some methodological elements were not applicable to the task at hand. For example, two references were selected for each primary recessive ataxia, and articles that provided evidence for a separate genetic basis with a clinical corollary of ataxia were preferred. Therefore, some articles that provided only detailed clinical description were not included. Moreover, inclusion criteria were clearly defined but there remained a place for interpretation to determine if cerebellar ataxia was a core feature of the phenotype and if the genotype-phenotype association was convincing. Thus, the classification of individual disorders between the three groups, i.e. as a recessive ataxia, a complex disorder with predominant ataxia or a disorder where ataxia is a secondary feature, remains a subjective appreciation and is open for discussion by a dedicated task force in order to reach a consensus. Finally, the search strategy was designed to be as sensible as possible, but ataxia is a frequent symptom in neurology, and it is possible that other ataxia-associated disorders could be considered for inclusion.

Important challenges remain to be addressed. First, the nosology of recessive ataxias is still highly confusing. Contrary to the dominantly inherited spinocerebellar ataxias, no universal acronym was adopted in the field of recessive ataxias, such that disorders were named based on the author who first described them, on regions of high prevalence, or according to clinical presentation. In the last few years, the term spinocerebellar ataxia, autosomal recessive (SCAR) was used to designate novel recessive ataxias, but this nomenclature did not include the previously described and most frequent ataxias. Moreover, as SCAR assignation was based on locus discovery, some of the included SCARs do not correspond to an identified gene. The term SPAX has also been used to designate ataxias with a strong spasticity component, irrespectively of their mode of inheritance. Recently, the International Parkinson and Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders recommended a nomenclature with a gene suffix in order to overcome the shortcomings of the numbered locus system, which include erroneously assigned loci, the mingling of causative and risk factor genes, unconfirmed causative associations, and inconsistent phenotypic correlations \[[@CR16]\]. These concerns are justified, although numbered naming systems present definite advantages for ease of use and proper delineation of the field. The nomenclature of recessive ataxias should be discussed by a dedicated task force of international experts in order to develop a naming system that reflects the complexity of the recessive ataxia phenotypes while allowing convenient clinical use.

Finally, large phenotypic variability exists between patients from different families and even from a single family with the same mutated gene, depending on the type of mutation and on its location in the gene. Other factors that affect age at onset and clinical course probably include the presence of modifier genes and environmental exposures. Hence, one could argue that the paradigm of one gene-one disease presented here does not reflect all the phenotypic variability observed, and could as well be replaced by the concept of one patient-one disease as we identify new genetic and environmental prognostic features that characterise more precisely the age at onset, evolution, and response to treatment. Such developments are likely to modify our understanding of genetic disorders and of their classification.

Conclusion {#Sec5}
==========

We present herein a classification of the autosomal recessive ataxias based on a systematic review of the literature. This work should serve as a framework for scientific discussion in order to bring together experts for the establishment of a much-needed consensus in this field.
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